Form 4: Vaxart Director W. Mark Watson Reports Stock Grant and Option Award

Director W. Mark Watson reported the acquisition of 16,000 common stock shares and an option to purchase 95,400 shares of Vaxart, Inc.

Summary

• On June 11, 2024, W. Mark Watson, a director of Vaxart, Inc., reported transactions involving the company's securities.
• Watson acquired 16,000 shares of common stock through the vesting of restricted stock units.
• He also acquired an option to purchase 95,400 shares of common stock at an exercise price of $0.77.
• The shares from the restricted stock units vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025.
• The options also vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment.

Key Dates